Retroperitoneal hematoma in patients with COVID-19 infection during anticoagulant therapy: A case series and literature review

Due to the hypercoagulable status of patients with severe COVID-19 infection, anticoagulants are often used to prevent thrombosis. However, these agents may cause bleeding events such as retroperitoneal hematoma (RPH). We report here on six patients with COVID-19 who developed RPH during treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi, Huriyeh, Moradi, Hazhir, Hashemi, Marzieh, Naderi, Zohre, Jafarpisheh, Saleh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465591/
https://www.ncbi.nlm.nih.gov/pubmed/36076361
http://dx.doi.org/10.1177/03000605221119662
Descripción
Sumario:Due to the hypercoagulable status of patients with severe COVID-19 infection, anticoagulants are often used to prevent thrombosis. However, these agents may cause bleeding events such as retroperitoneal hematoma (RPH). We report here on six patients with COVID-19 who developed RPH during treatment. Early evidence of bleeding led to confirmatory diagnosis with imaging. Four patients recovered with supportive treatment (IV fluids and blood transfusions) and two patients recovered by angioembolization. RPH should be considered in COVID patients on anticoagulants as soon as haemoglobin or blood pressure falls. Further studies are required to provide guidance and recommendations on use of anticoagulants in critically ill patients with COVID-19.

Ejemplares similares